bardoxolone-methyl and Colonic-Neoplasms

Seventeen CDDO-amino acid-NO donor trihybrids (4a-q) were designed and synthesized. Biological evaluation indicated that the most active compound 4c produced high levels of NO and inhibited the proliferation of drug-sensitive (HCT-8, IC50 = 0.294 μM) and drug-resistant (HCT-8/5-FU, IC50 = 0.232 μM) colon cancer cells, which were attenuated by an NO scavenger or typical substrate of PepT1. Furthermore, 4c triggered HCT-8 and HCT-8/5-FU cell apoptosis more strongly than CDDO-Me, inhibited the HIF-1α, Stat3, AKT, and ERK signaling, and induced the nitration of P-gp, MRP1, and BCRP proteins in HCT-8/5-FU cells. Finally, 4c had 4.36-5.53-fold less inhibitory activity against nontumor colon epithelial-like cells (CCD841, IC50 = 1.282 μM) in vitro and inhibited the growth of implanted human drug-resistant colon cancers in mice more potently than CDDO-Me. Together, 4c is a novel trihybrid with potent antitumor activity and may be a promising candidate for the treatment of drug-resistant colon cancer.

Topics: Amino Acids; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Molecular Structure; Nitric Oxide Donors; Oleanolic Acid; Signal Transduction; Structure-Activity Relationship; Tumor Cells, Cultured; Xenograft Model Antitumor Assays